nach oben

Erschienen in:

01.01.2010 | Drug Reactions and Interactions

Glitazones accelerate bone loss and increase the risk of fracture in patients with type 2 diabetes mellitus

Erschienen in: Drugs & Therapy Perspectives | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Excerpt

Thiazolidinediones, which are commonly known as glitazones, are used in the treatment of type 2 diabetes mellitus. Through their activation of peroxisome proliferator-activated receptor-γ nuclear transcription factor, glitazones may decrease bone formation, leading to decreased bone mineral density and an increased risk of fractures, particularly in women. Currently, there are no data on whether any treatments mitigate glitazone-induced adverse skeletal effects. …

Bodmer M, Meier C, Kraenzlin ME, et al. Risk of fractures with glitazones: a critical review of the evidence to date. Drug Saf 2009; 32(7): 539–47PubMedCrossRef

Okazaki R, Miura M, Toriumi M, et al. Short-term treatment with troglitazone decreases bone turnover in patients with type 2 diabetes mellitus. Endocr J 1999; 46(6): 795–801PubMedCrossRef

Berberoglu Z, Gursoy A, Bayraktar N, et al. Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women. J Clin Endocrinol Metab 2007 Sep; 92(9): 3523–30PubMedCrossRef

Grey A, Bolland M, Gamble G, et al. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2007; 92(4): 1305–10PubMedCrossRef

Glintborg D, Andersen M, Hagen C, et al. Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. J Clin Endocrinol Metab 2008; 93(5): 1696–701PubMedCrossRef

Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009; 180(1): 32–9PubMedCrossRef

Meier C, Kraenzlin ME, Bodmer M, et al. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008; 168(8): 820–5PubMedCrossRef

Yaturu S, Bryant B, Jain SK. Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care 2007; 30(6): 1574–6PubMedCrossRef

Dormuth CR, Carney G, Carleton B, et al. Thiazolidinediones and fractures in men and women. Arch Intern Med 2009; 169(15): 1395–402PubMedCrossRef

10.

Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009; 373(9681): 2125–35PubMedCrossRef

11.

Kahn SE, Zinman B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008; 31(5): 845–51PubMedCrossRef

Titel: Glitazones accelerate bone loss and increase the risk of fracture in patients with type 2 diabetes mellitus
Publikationsdatum: 01.01.2010
Verlag: Springer International Publishing
Erschienen in: Drugs & Therapy Perspectives / Ausgabe 1/2010
Print ISSN: 1172-0360
Elektronische ISSN: 1179-1977
DOI: https://doi.org/10.2165/11203640-000000000-00000

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2010

Worldwide control of trachoma involves a strategy combining surgery, antibacterials, facial cleanliness and environmental improvements

Aggressive treatment is essential to reduce cardiovascular risk in diabetic hypertensive patients

Ferric carboxymaltose: a guide to its use in iron-deficiency anaemia

Fesoterodine: a guide to its use in overactive bladder syndrome

Antidepressants are the main options for the long-term pharmacological treatment of generalized anxiety disorder

First reports of serious adverse drug reactions in recent weeks